Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-31
2006-01-31
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S384000, C530S395000, C530S412000, C530S416000, C424S078100, C424S078110
Reexamination Certificate
active
06992061
ABSTRACT:
The invention relates to a method of removing endotoxin from preparation of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this depyrogenation step, and to the depyrogenated product and its clinical uses.
REFERENCES:
patent: 3998946 (1976-12-01), Condie et al.
patent: WO 95/07703 (1995-03-01), None
patent: 95/22556 (1995-08-01), None
Botten et al., European Juornal of Immunology, vol. 22, No. 10, pp. 2687-2695, Oct. 1992.
Libert et al., J. Exp. Med., vol. 180, pp. 1571-1575, Oct. 1994.
Boutten, A., et al., “Alpha1-Acid Glycoprotein Potentiates Lipopolysaccharide-induced Secretion of Interleukin-1 Beta, Interleukin-6 and Tumor Necrosis Factor-alpha by Human Monocytes and Alveolar and Peritoneal Macrophages”,European Journal of Immunology, 22(10), pp. 2687-2695, (Oct. 1992).
Chen, R.F., “Removal of Fatty Acids from Serum Albumin by Charcoal Treatment”,The Journal of Biological Chemistry, 242(2), pp. 173-181, (Jan. 25, 1967).
Edwards, C.A., et al., “Tri (n-Butyl) Phosphate/Detergent Treatment of Licensed Therapeutic and Experimental Blood Derivativesl”,International Journal Vox Sanguinis of Transfusion Medicine, 52, pp. 53-59, (1987).
Hao, Y., et al., “Development of Large-Scale Fractionation Methods IV. A Simple Method For the Large-Scale Preparation of alpha1-Acid Glycoprotein”,Biochimica Et Biophysica Acta(P),322(1), pp. 99-108, (Sep. 21, 1973).
Kistler, P., et al., “Large Scale Production of Human Plasma Fractions”,Vox Sanguinis, 7, pp. 414-424, (1962).
Libert, C., et al., “Protection by alpha1-acid Glycoprotein Against Tumor Necrosis Factor-induced Lethality”,J. Exp. Med., 180, 1571-1575, (Oct. 1994).
Pentel, P.R., et al., “Effects of High Dose Alpha-1-Acid Glycoprotein on Despiramine Toxicity in Rats”,Journal of Pharmacology and Experimental Therapeutics, 246(3), 1061-1066, (1988).
Weary, M., “Depyrogenation, in”,PYROGENS: Endotoxins, LAL Testing, and Depyrogenation, Frederick C. Perason ed., Marcel Dekker, Inc., 203-218, (1985).
Keyler, Daniel E., “Effects of Alpha-1-Acid Glycoprotein Administration on Propranolol Binding and Beta Blockade in Rats”,Biochemical Pharmacology, vol. 38, No. 7, (1989),1163-1168.
Kremer, Josephina M., “Drug Binding to Human Alpha-1-acid Glycoprotein in Health and Disease”,Pharmacological Reviews, vol. 40, No. 1, (1988),1-47.
Seaberg, David C., “Effects of Alpha-1-acid Glycoprotein on the Cardiovascular Toxicity of Nortriptyline in a Swine Model”,Vet Hum Toxicol, vol. 33, No. 3, (Jun. 1991),226-231.
Lewin David Roger
More John Edward
Rott Jacqueline
Mohamed Abdel A.
National Blood Authority
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Purification method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purification method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purification method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3600264